Are Preferences for Cyclooxygenase-2 Inhibitors Influenced by the Certainty Effect?

Journal of Rheumatology

Volumn 31, Issue 3, 2004, Pages 591-593

  Fraenkel, Liana ^a,b   Wittink, Dick R ^c   Concato, John ^a,b   Fried, Terri ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c YALE UNIVERSITY   (United States)

Author keywords

Arthritis; Conjoint analysis; Cyclooxygenase 2 inhibitors; Nonsteroidal antiinflammatory drugs; Treatment preferences

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; DIGESTIVE SYSTEM ULCER; DRUG CHOICE; DRUG COST; DYSPEPSIA; EDUCATION; FEMALE; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HUMAN; KNEE PAIN; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; PREDICTION; PRIORITY JOURNAL; QUESTIONNAIRE; RISK REDUCTION;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PATIENT SATISFACTION; PERCEPTION; PREDICTIVE VALUE OF TESTS; RISK;

EID: 1542619705     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. JAMA 2000;284:1247-55.
2. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8.
3. Fraenkel L, Bogardus S, Concato J, Felson D. Unwillingness of rheumatoid arthritis patients to accept the risk of adverse effects. Rheumatology 2002;41:253-61.
4. Pullar T, Wright V, Feely M. What do patients and rheumatologist regard as an acceptable' risk in the treatment of rheumatic disease? Br J Rheumatol 1990;29:215-8.
5. O'Brien BJ, Elswood J, Calin A. Willingness to accept risk in the treatment of rheumatic disease. J Epidemiol Comm Health 1990;44:249-52.
6. Ho M, Lavery B, Pullar T. The risk of treatment: a study of rheumatoid arthritis patients' attitudes. Br J Rheumatol 1998;37:459-60.
7. Plous S. The psychology of judgement and decision making. New York: McGraw-Hill Inc.; 1993.
8. Tversky A, Kahneman D. The framing of decisions and the psychology of choice. Science 1981;211:453-8.
9. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to anti-rheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833-40.
10. Wittink DR, Bergenstuen T. Forecasting with conjoint analysis. In: Armstrong JS, editor. Principles of forecasting: a handbook for researchers and practitioners. Norwell, MA: Kluwer Academic Publishers; 2001.
11. Wittink DR, Bergenstuen T. Forecasting with conjoint analysis. In: Armstrong JS, editor. Principles of forecasting: a handbook for researchers and practitioners. Norwell, MA: Kluwer Academic Publishers; 2001.
12. Johnson RM. Adaptive conjoint analysis. In: Proceedings, Sawtooth Software Conference on Perceptual Mapping, Conjoint Analysis, and Computer Interviewing. Ketchum, ID: Sawtooth, Software; 1987:253-65.
13. Cannon GW, Caldwell JR, Holt P, et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group. Arthritis Rheum 2000;43:978-87.
14. Rothman AJ, Kiviniemi MT. Treating people with information: an analysis and review of approaches to communicating health risk information. Monogr Natl Cancer Inst 1999;25:44-51.
15. Mazur DJ, Hickam DH. Patients' interpretations of probability terms. J Gen Intern Med 1991;6:237-40.
16. Laudan L. The book of risks. New York: John Wiley & Sons, Inc.; 1994.
17. Langman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999;282:1929-33.
18. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:241-9.
19. Singh G, Ramey DR, Triadafilopoulos G, Brown BW, Balise RR. GI SCORE: A simple self-assessment instrument to quantify the risk of serious NSAID-related GI complications in RA and OA [abstract]. Arthritis Rheum 1998;41 Suppl:S75.
20. Towheed TE, Hochberg MC. A systematic review of randomized controlled trials of pharmacological therapy in osteoarthritis of the knee, with emphasis on trial methodology. Semin Arthritis Rheum 1997;26:755-70.
21. Fraenkel L, Bogardus ST, Wittink DR. Understanding patient preferences for the treatment of lupus nephritis using adaptive conjoint analysis. Med Care 2001;39:1203-16.
22. Loewenstein GF, Hsee CK, Weber EU, Welch N. Risk as feelings. Psychol Bull 2001;127:267-86.